Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 1993 Oct 01;82(7):2235-8 PMID: 8400272

Pubmed ID

8400272

Abstract

We analyzed the outcome of 450 HLA-identical sibling bone marrow transplants for chronic myelogenous leukemia (CML) in chronic phase performed between 1985 and 1990 and reported to the International Bone Marrow Transplant Registry (IBMTR). All patients received either hydroxyurea (n = 292) or busulfan (n = 158) to treat their CML before transplant. The median interval between diagnosis and transplant was 10 months (range, 1 to 191). Patients treated with hydroxyurea had a higher probability (95% confidence interval) of leukemia-free survival (LFS) at 3 years than those treated with busulfan (61% [51% to 70%] v 45% [36% to 55%], P < .0003). Probability of LFS was also higher in patients transplanted within 1 year of diagnosis (61% [53 to 68%] v 47% [38% to 57%], P < .001). After adjustment for patient and transplant covariables in a multivariate analysis, prior chemotherapy and duration of disease pretransplant were independently associated with LFS. These data support the use of hydroxyurea rather than busulfan and transplant within 1 year of diagnosis for patients with CML and an HLA-identical sibling.

Author List

Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, Dicke KA, Gluckman E, Herzig RH, Marmont A

Author

Mary M. Horowitz MD, MS Center Director, Professor in the Medicine department at Medical College of Wisconsin




Scopus

2-s2.0-0027504040   182 Citations

MESH terms used to index this publication - Major topics in bold

Actuarial Analysis
Bone Marrow Transplantation
Busulfan
Follow-Up Studies
Humans
Hydroxyurea
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Probability
Recurrence
Survival Analysis
Time Factors
jenkins-FCD Prod-299 9ef562391eceb2b8f95265c767fbba1ce5a52fd6